drugset
drugset / Trial / NCT00212628

Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan

NCT00212628 ↗

Phase 3 Completed 444 enrolled Ono Pharmaceutical Co., Ltd. Astellas Pharma Inc · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of ONO-5920 in patients with involutional osteoporosis.

Timeline

Start
2004-06
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Minodronic acid Small molecule — —

Indications

osteoporosis